Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-120762
Filing Date
2025-05-15
Accepted
2025-05-15 16:00:30
Documents
56
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d903288d10q.htm   iXBRL 10-Q 650721
2 EX-31.1 d903288dex311.htm EX-31.1 6788
3 EX-31.2 d903288dex312.htm EX-31.2 6818
4 EX-32.1 d903288dex321.htm EX-32.1 3690
5 EX-32.2 d903288dex322.htm EX-32.2 3433
  Complete submission text file 0001193125-25-120762.txt   3769684

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA vinc-20250331.xsd EX-101.SCH 30830
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vinc-20250331_cal.xml EX-101.CAL 25463
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vinc-20250331_def.xml EX-101.DEF 161338
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20250331_lab.xml EX-101.LAB 275189
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20250331_pre.xml EX-101.PRE 230398
59 EXTRACTED XBRL INSTANCE DOCUMENT d903288d10q_htm.xml XML 461784
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

EIN.: 833197402 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39244 | Film No.: 25952322
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)